Harmony Biosciences (NASDAQ:HRMY) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock. Several other research analysts also recently weighed in on HRMY. Bank of America restated an underperform rating and issued […]

Related Keywords

United States ,America ,Jeffrey Dierks ,Charles Schwab Investment Management Inc ,Cantor Fitzgerald ,Needham Company ,Jupiter Asset Management Ltd ,Janney Montgomery Scott ,Goldman Sachs Group ,Harmony Biosciences Holdings Inc ,Harmony Biosciences ,Free Report ,Moderate Buy ,Get Free Report ,Schwab Investment Management ,Capital Partners ,Forest Capital Management ,Montgomery Scott ,Jupiter Asset Management ,Biosciences Holdings ,Harmony Biosciences Daily ,